Champions Oncology, Inc. cash flow to debt ratio of 160.88% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Champions Oncology, Inc.'s free cash flow has increased -200.34% from $-6.97M last year to $7.00M, signaling increasing performance

Champions Oncology, Inc.'s debt to equity ratio is 1.17, which means that the company's assets are unhealthy financed, signaling financial risk.

Champions Oncology, Inc.'s debt has decreased relative to shareholder equity from 1.62 last year to 1.17 today, signaling strengthened financials

Champions Oncology, Inc. has a net cash position, so leverage is healthy.

Interest expense is not separately reported in Champions Oncology, Inc.'s latest filing, so interest coverage cannot be calculated.

Champions Oncology, Inc.'s profit margin has decreased (123.95%) in the last year from 8.26% to -1.98%, signaling decreasing performance

Champions Oncology, Inc.'s short-term liabilities of $19.92M exceed its short-term assets of $19.22M, signaling financial risk

Champions Oncology, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Champions Oncology, Inc.'s return on equity of -29.56%, is lower than 15.00%, indicating bad performance

Champions Oncology, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Champions Oncology, Inc. had positive net income in only 2 out of 5 years, indicating unstable earnings

Champions Oncology, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Champions Oncology, Inc. has a free cash flow yield of 9.80%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Champions Oncology, Inc.'s yearly earnings has decreased 124.99% since last year from $4.70M to $-1.18M, signaling decreasing performance

Champions Oncology, Inc.'s yearly revenue has decreased 100.00% since last year from $56.94M to $0.00, signaling decreasing performance

ROIC -13.15% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Champions Oncology, Inc.'s 3-year revenue CAGR of 3.33% is positive, indicating growing revenue over the past 3 years

Champions Oncology, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Champions Oncology, Inc. had positive ROE in only 2 out of 5 years, indicating inconsistent returns on equity

Champions Oncology, Inc. is undervalued relative to its fair value price of 9.21 based on Discounted Cash Flow model

Champions Oncology, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Champions Oncology, Inc. is overvalued relative to its fair value price of 3.44 based on EBITDA multiple model

Champions Oncology, Inc. has an EV/EBITDA ratio of 158.78x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Champions Oncology, Inc. is overvalued relative to its fair value price of -1.55 based on Earnings Fair Value model

Champions Oncology, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Champions Oncology, Inc. has a price-to-book ratio of 17.48x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Champions Oncology, Inc. has a price-to-sales ratio of 1.20x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue